Status:
NOT_YET_RECRUITING
ADAM'S Prognostic Markers
Lead Sponsor:
Assiut University
Conditions:
Acute Disseminated Encephalomyelitis
Eligibility:
All Genders
6-18 years
Brief Summary
Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating disorder of the central nervous system that predominantly affects children. It typically presents with an acute onset of...
Detailed Description
* To evaluate the prognostic value of cerebrospinal fluid (CSF) and magnetic resonanceimaging (MRI) findings at initial presentation in predicting six months neurological outcomes in pediatric patient...
Eligibility Criteria
Inclusion
- \- First episode of acute disseminated encephalomyelitis( ADEM).
- \- MRI and cerebrospinal fluid (CSF) performed within 7 days of symptom onset.
- \- Age from 6 months up to 18 years
Exclusion
- \- History of prior demyelinating events
- \- Alternative diagnoses (e.g., CNS infections, metabolic disorders).
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT07188194
Start Date
September 1 2025
End Date
October 1 2026
Last Update
September 23 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.